Activity of Vinorelbine on B-Chronic Lymphocytic Leukemia Cells In Vitro

  • P. A. Bernabei
  • I. Landini
  • B. Bartolozzi
  • I. Banchelli
  • A. Degli Innocenti o Nocentini
  • V. Santini
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 457)

Summary

Vinorelbine (VNR) is a new semi-synthetic Vinca rosea alkaloid that has been employed both in combination and as a single agent, showing a significant antitumour activity. Since little is known about VNR in human leukemia, we studied the in vitro cytotoxic effect of VNR on peripheral blood lymphocytes from 18 patients affected by B-chronic lymphocytic leukemia (CLL), employing the INT assay. VNR inhibited fresh B-CLL cells from 15/18 patients in primary cultures, the ID50 doses ranging from 4 ng/ml to 83 μg/ml. These data strongly suggest that VNR could be effective in the treatment of B-CLL.

Keywords

Vinorelbine In vitro sensitivity testing INT assay Chronic Lymphocytic Leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Potier P. The synthesis of Navelbine-prototype of a new series of vinblastine derivates. Semin. Oncol. 16 Supp. 4:2–4, 1989.PubMedGoogle Scholar
  2. 2.
    Goa K.L. and Foulds D. Vinorelbine. A review of its pharmacological properties and clinical use in cancer therapy. Drug and Aging 5(3): 200–234, 1994.CrossRefGoogle Scholar
  3. 3.
    Meininger V., Binet S., Chaineau E., et al. In situ response to vinca alkaloids by microtubules in coltured post-implanted mouse embryos. Biol. Cell 60:21–29, 1990.Google Scholar
  4. 4.
    Binet S., Chaineau E., Fellus A., et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int. J. Cancer 46:262–266, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Cheson B.D:, Bennet J.M:, Rai K.R., et al. Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL). Recommandation of the NCI-Sponsored Working Group. Am. J. Hematol. 29: 152, 1988.PubMedCrossRefGoogle Scholar
  6. 6.
    Rai K.R., Sawitsky A., Cronkite E.P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46: 219, 1975.PubMedGoogle Scholar
  7. 7.
    Bernabei P.A., Santini V., Silvestro L., Dal Pozzo O., Bezzini R:, Gattei V., Saccardi R., Rossi Ferrini P. In vitro chemosensivity testing of leukemic cells. Development of a semiautomated colorimetric assay. Hematol. Onc. 7:243–253, 1989.CrossRefGoogle Scholar
  8. 8.
    Salomon S.E: Application of the human tumour stem cell assay to new drug evaluation and screening. In Salomon S.E. (ed), Cloning of human stem cell. New York: Alan R. Liss Inc. 223, 1980.Google Scholar
  9. 9.
    Santini V., Bernabei P.A., Silvestri L., Dal Pozzo O., Bezzini R., Viano I., Gattei V., Saccardi R., Rossi Ferrini P. In Vitro Chemosensivity testing of leukemic cells: prediction of response to chemotherapy in patients whit acute non-lymphoblastic leukemia. Hematological Oncology vol. 7 287–293, 1989.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaspers G.J.L., Veerman A.P.J., Van Zantwijk C.H., Smets L.A., Van Wering E.K., Van Der-Does-Van Den Berg. In vitro cellular drug resistance and prognosis in newly diagnosed childhood Acute Lymphoblastic Leukemia. Blood 2723–2729, 1997.Google Scholar
  11. 11.
    Bruno S., Savignano R., Corrado C., et al. Vinorelbine (VNR): a new vinka alkaloid active in refractary/relapsed Lymphomas. A phase II study (Abstract n° 1300) Proceeding of ASCO 13:383, 1995.Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • P. A. Bernabei
    • 1
  • I. Landini
    • 1
  • B. Bartolozzi
    • 1
  • I. Banchelli
    • 1
  • A. Degli Innocenti o Nocentini
    • 1
  • V. Santini
    • 1
  1. 1.U.O. EmatologiaUniversità degli Studi-Azienda Ospedaliera di CareggiFirenzeItaly

Personalised recommendations